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Cholera toxin (CT) is an AB5 toxin that moves from the cell
surface to the endoplasmic reticulum (ER) by retrograde vesicular transport. In the ER, the catalytic A1 subunit dissociates
from the rest of the toxin and enters the cytosol by exploiting the
quality control system of ER-associated degradation (ERAD).
The driving force for CTA1 dislocation into the cytosol is
unknown. Here, we demonstrate that the cytosolic chaperone
Hsp90 is required for CTA1 passage into the cytosol. Hsp90
bound to CTA1 in an ATP-dependent manner that was blocked
by geldanamycin (GA), an established Hsp90 inhibitor. CT
activity against cultured cells and ileal loops was also blocked by
GA, as was the ER-to-cytosol export of CTA1. Experiments
using RNA interference or N-ethylcarboxamidoadenosine, a
drug that inhibits ER-localized GRP94 but not cytosolic Hsp90,
confirmed that the inhibitory effects of GA resulted specifically
from the loss of Hsp90 activity. This work establishes a functional role for Hsp90 in the ERAD-mediated dislocation of
CTA1.

Cholera toxin (CT)4 is one of the main virulence factors produced by Vibrio cholerae (1, 2). It is an AB-type protein toxin
that contains separate catalytic and cell-binding subunits. The
catalytic A subunit is initially synthesized as a 27 kDa protein,
which undergoes proteolytic nicking to generate a disulfidelinked CTA1/CTA2 heterodimer. The ADP-ribosyltransferase
activity of CT resides in the 22 kDa CTA1 polypeptide, while
the 5 kDa CTA2 polypeptide maintains numerous non-covalent interactions with the B subunit and thereby links the
enzymatic A1 moiety to the cell-binding B moiety. The CTB
subunit, built from 11 kDa monomers, is a homopentameric
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ring-like structure that binds to GM1 gangliosides on the
plasma membrane of a target cell.
CT travels as an intact holotoxin from the cell surface to the
ER (3). Environmental conditions in the ER facilitate reduction
of the CTA1/CTA2 disulfide bond and dissociation of CTA1
from CTA2/CTB5. This process occurs at the resident redox
state of the ER and involves the action of protein-disulfide
isomerase (PDI), an ER-localized oxidoreductase (4 – 8). Unfolding of the dissociated CTA1 subunit allows it to move into
the cytosol through one or more protein-conducting channels
in the ER membrane (9 –11). Cytosolic CTA1 then refolds into
an active conformation and modifies its Gs␣ target.
ER-associated degradation (ERAD), a host quality control
mechanism, is responsible for the ER-to-cytosol dislocation
of CTA1 (12–14). A variety of ER-localized chaperones, lectins, and oxidoreductases function in ERAD (15–17). These
proteins recognize features that are present in misfolded
proteins such as surface-exposed hydrophobic residues or
improper patterns of N-linked glycosylation. When a misfolded
protein is identified by the ERAD system, it is exported to the
cytosol through Sec61 and/or Derlin-1 protein-conducting
channels. Dislocated ERAD substrates are usually appended
with polyubiquitin chains that serve as a molecular tag for degradation by the 26 S proteasome. However, CTA1 avoids the
standard ERAD route of ubiquitin-dependent proteasomal
degradation because it has a paucity of lysine residues for ubiquitin conjugation (18, 19).
ERAD substrates are extracted from the ER through a mechanism that often involves the AAA ATPase Cdc48/p97 (16).
However, p97 appears to play a minimal role in CTA1 dislocation (20, 21). An alternative model has proposed a ratchet
mechanism, which involves the spontaneous refolding of CTA1
as it enters the cytosol (19). Recent CTA1 structural studies do
not support this model, as it has been shown that the isolated
CTA1 subunit is a partially disordered, thermally unstable protein (22–24). Because CTA1 is in an unfolded conformation at
37 °C, an as yet unidentified host protein must provide the driving force for CTA1 extraction from the ER.
In this report we demonstrate that Hsp90 is required for
CTA1 dislocation to the cytosol. The loss of Hsp90 function did
not prevent CT transport to the ER but did inhibit the ERto-cytosol export of CTA1. This, in turn, blocked CT activity
against both cultured cells and ileal loops. Hsp90 has been
shown to maintain membrane-embedded ERAD substrates in a
soluble state and to help determine the fate of misfolded proJOURNAL OF BIOLOGICAL CHEMISTRY
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teins (25, 26). This work establishes a new role for Hsp90 in the
extraction of a soluble ERAD substrate from the ER.

EXPERIMENTAL PROCEDURES
Materials—CT was purchased from List Biological Laboratories (Campbell, CA); His-tagged CTA1 was purified
in the laboratory as previously described (24). Cell culture
and transfection reagents were purchased from Invitrogen
(Carlsbad, CA). Geldanamycin (GA) was purchased from
Stressgen (Ann Arbor, MI), while N-ethylcarboxamidoadenosine (NECA), MG132, ALLN, and Brefeldin A (BfA) were
purchased from Sigma-Aldrich.
Surface Plasmon Resonance (SPR)—Experiments with the
Reichert (Depew, NY) SR7000 SPR Refractometer were performed as previously described (22, 24). To detect toxinchaperone interactions, the SPR sensor slide was coated with a
His-tagged CTA1 construct (22). Binding affinities and stoichiometries were calculated using the BioLogic (Campbell,
Australia) Scrubber 2 software. To detect CTA1 in the cytosol
or medium of toxin-treated cells, the SPR sensor slide was
coated with an anti-CTA1 antibody (24). CTA standards (100,
10, 1, and 0.1 ng/ml) from Calbiochem (La Jolla, CA) were used
for these experiments; only the 1 and 0.1 ng/ml standards are
shown on the SPR traces for scaling purposes. The cytosolic
samples used for this assay were brought to a final volume of 1
ml, thus allowing for a direct comparison between the standards and experimental samples.
Toxicity Assays—Cells continually exposed to various
concentrations of CT for 2 h in the absence or presence of
drug treatment were analyzed for cAMP content using an
[125I]cAMP competition assay from Perkin-Elmer (Boston,
MA) as previously described (24). Cells continually exposed to
various concentrations of ricin for 4 h in the absence or presence of drug treatment were analyzed for protein synthesis levels by the incorporation of [35S]methionine (Perkin-Elmer) into
newly synthesized proteins (13). Cells grown in 24-well plates
were used for these experiments.
A rat ligated ileal loop model was used to evaluate the in
vivo effect of GA on CT enterotoxicity. Sprague-Dawley rats
(n ⫽ 4) between 90 –120 g in weight were used. Rats were
starved for 16 h before initiating the assays. All animal experiments were done after approval from the CINVESTAV-IPN
Animal Ethical Committee (CICUAL). To perform laparotomy
and exposing the small intestines, animals were anesthetized
with xylacin (6.5 mg/kg) and ketamin (34.5 mg/kg). Once the
intestines were exposed, the ileocecal valve was localized, and,
20 cm upstream on the small intestine, four ileal loops of 3 cm
with 2– 4 cm between them were ligated. The ileal loops were
inoculated with 200 l of CT, at 2 g/ml in phosphate-buffered
saline (PBS), alone or with 15 M of GA. Two other loops were
injected with 200 l of 15 M GA alone or with 200 l of PBS.
Preliminary experiments indicated that 9 M GA was not an
effective inhibitory concentration, and that 25 M GA produced results similar to those obtained with 15 M GA. After
inoculums, intestines were returned to the abdominal cavity
and the incision was sutured. Inoculated rats were kept alive
during 7 h and then sacrificed by cervical dislocation. Ileal loops
were photographed and dissected; the intestinal contents were
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collected by gentle pressure. The volume of fluid in each loop
was measured and expressed as a ratio of the amount (l) of
fluid per unit length (cm) of loop.
Dislocation and Secretion Assays—Experiments were performed as previously described (24). In brief, HeLa cells were
incubated at 4 °C for 30 min with 1 g/ml of CT. The cells were
then chased at 37 °C for 2 h in toxin-free medium lacking or
containing the specified drugs. Media samples were collected,
and the cells were lifted from the plate with EDTA in PBS. The
collected cell pellet was resuspended in 1 ml (SPR assay) or 0.1
ml (Western blot analysis) HCN buffer (50 mM Hepes pH 7.5,
150 mM NaCl, 2 mM CaCl2, 10 mM N-ethylmaleimide, and a
protease inhibitor mixture) containing 0.04% digitonin (Calbiochem). After 10 min at 4 °C, cytosolic (i.e. supernatant) and
organelle (i.e. pellet) fractions were collected by centrifugation.
For Western blot analysis, 120 l of 1⫻ sample buffer was
added to the pellet and 20 l of 4⫻ sample buffer was added to
the supernatant. Cells were grown in 6-well plates for these
experiments; three wells were used for each condition.
Western Blot Analysis—As previously described (24), antibodies used in Western blot analysis were rabbit anti-Hsp90
(Stressgen) at 1:20,000 dilution, rabbit anti-PDI (Stressgen) at
1:5,000 dilution, rabbit anti-CTA (Sigma-Aldrich) at 1:20,000
dilution, rabbit anti-actin (Abcam, Cambridge, MA) at 1:10,000
dilution, and horseradish-peroxidase-conjugated goat anti-rabbit
IgG (Jackson Immunoresearch Laboratories, West Grove, PA) at
1:20,000 dilution. Separate blots were run for each protein,
except for Hsp90 and actin which were probed on the same
blot. Samples were resolved by reducing or non-reducing SDSPAGE with 15% polyacrylamide gels. When determining the
fidelity of our fractionation procedure, anti-Hsp90 and antiPDI blots each detected only a single band of the expected
molecular mass on the entire gel.
Transfection and Immunoprecipitation—CHO cells seeded
to 80% confluency in 6-well plates were transfected with
pcDNA3.1/ssCTA1 (27) using Lipofectamine (Invitrogen) according to the manufacturer’s instructions. At 24 h post-transfection, cells were incubated in methionine-free medium for 1 h
before [35S]methionine was added for another hour. Where
indicated, 0.1 M NECA or 0.1 M GA was present during
both the methionine starvation and the radiolabeling. Digitonin was then used to generate membrane and cytosolic
fractions as described above. Both fractions were immunoprecipitated with an anti-CTA antibody. SDS-PAGE with
PhosphorImager analysis was used to visualize and quantify
the immunoisolated material. Control experiments with
mock transfected cells did not detect the 21 kDa protein
immunoisolated from cells transfected with pcDNA3.1/
ssCTA1. The extent of CTA1 dislocation for each experimental
condition was calculated with the following equation: % cytosolic CTA1 ⫽ CTA1 supernatant signal/[CTA1 supernatant
signal ⫹ CTA1 pellet signal]. The percentage obtained from
untreated control cells was then set as a 100% value, and the
percentages obtained from the experimental conditions were
expressed as a fraction of the 100% control value.
RNA Interference (RNAi)—1.5 ⫻ 104 HeLa cells were seeded
to 24-well plates in DMEM supplemented with 10% fetal bovine
serum (Atlanta Biologicals) the day before transfection. Cells
VOLUME 285 • NUMBER 41 • OCTOBER 8, 2010

Role of Hsp90 in ERAD-mediated Dislocation
added to each well. Transfection
reagents were prepared in Optimem-reduced serum media. Lipofectamine 2000 was diluted 1:50 in
Optimem and allowed to incubate
for 10 min at room temperature. In
separate tubes, Hsp90␣/␤ siRNA
and control siRNA-A (Santa Cruz
Biotechnology, Santa Cruz, CA)
were diluted to 10 nM in Optimem
and allowed to incubate for 10 min
at room temperature. The diluted
siRNAs and Lipofectamine 2000
were then combined and allowed to
FIGURE 1. GA but not NECA inhibits the interaction between CTA1 and Hsp90. Either Hsp90 (A) or GRP94 (B)
was perfused over a CTA1-coated SPR sensor slide at 37 °C under the following conditions: no ATP in the incubate at room temperature for
perfusion buffer, ATP in the perfusion buffer, ATP and GA in the perfusion buffer, or ATP and NECA in the 20 min. 100 l of the appropriate
perfusion buffer. Ligand was removed from the perfusion buffer 240 s into the experiment. One of four repre- mixture was then added to the cells.
sentative experiments is shown. In panel B, *** indicates all experimental conditions other than GRP94 ⫹ ATP.
After an overnight incubation at
37 °C and 5% CO2, 50 l of 100%
fetal bovine serum was added to each well. The cells were incubated for another 24 h before experiments were performed.

FIGURE 2. Binding of CTA1 to Hsp90 or GRP94. A, Hsp90 was perfused over a
CTA1-coated SPR sensor slide at 100, 400, 800, 1,600, and 3,200 nM concentrations. The ligand was removed from the perfusion buffer after 115 s. B, GRP94 was
perfused over a CTA1-coated SPR sensor slide at 100, 200, 400, 800, and 1,600 nM
concentrations. The ligand was removed from the perfusion buffer after 118 s.
Note that the results for Hsp90 and GRP94 are plotted on different scales. For all
conditions, ATP was present in the 37 °C perfusion buffer. Measurements collected from three independent experiments are shown. The orange lines represent best fit curves derived from the raw data using 1:2 (CTA1:Hsp90 or CTA1:
GRP94) binding models. The SPR traces display, from top to bottom of the graph,
results for decreasing concentrations of the ligand.

were incubated at 37 °C with 5% CO2 overnight and allowed
to reach 60 – 80% confluency. On the day of transfection,
cells were washed twice with PBS before 0.4 ml of DMEM was
OCTOBER 8, 2010 • VOLUME 285 • NUMBER 41

RESULTS AND DISCUSSION
Hsp90 functions in toxin translocation across the endosomal
membrane (28 –30), but its potential role in ERAD-mediated
toxin dislocation has not been examined. To address this issue,
SPR was used to determine whether Hsp90 could directly interact with the isolated CTA1 subunit at physiological temperature (Fig. 1A). Hsp90 binding to CTA1 occurred in an ATP-dependent manner that was blocked by GA. This demonstrated
that Hsp90 could bind to CTA1 at 37 °C. Because CTA1 is in an
unfolded conformation at 37 °C (22, 24), this also suggested that
Hsp90 recognizes an unfolded conformation of CTA1 during
the dislocation event. The interaction between CTA1 and
Hsp90-ATP was not substantially affected by NECA, a drug
that inhibits GRP94 but not Hsp90. GRP94, an ER-localized
Hsp90, also bound to CTA1 in an ATP-dependent process that
was blocked by both GA and NECA (Fig. 1B). The interaction
between Hsp90 and CTA1 was much stronger than the interaction between GRP94 and CTA1: Hsp90 bound to CTA1 with
a KD of 7 nM, whereas GRP94 bound to CTA1 with a KD of 292
nM (Fig. 2 and Table 1). Consistent with the dimeric natures of
Hsp90 and GRP94 (31), both chaperones bound to CTA1 in a
2:1 ratio of chaperone:toxin (Fig. 2). The specific, high-affinity
interaction between Hsp90-ATP and CTA1 indicated that
Hsp90 could be involved with the CT intoxication process.
To detect a functional role for Hsp90 in CT intoxication, CT
toxicity assays were performed in the presence or absence of
GA (Fig. 3A). The elevated levels of cAMP resulting from CT
intoxication were strongly inhibited in GA-treated cells.
Whereas CT activity against untreated control cells exhibited a
half-maximal effective concentration at 4 ng CT/ml, GAtreated cells only produced 36% of the maximal cAMP response
when exposed to 100 ng CT/ml. Thus, at least 25-fold higher
concentrations of CT would be required to elicit the same
degree of intoxication in GA-treated cells as compared with the
untreated control cells. In contrast, NECA-treated cells exhibited the same level of sensitivity to CT as the untreated control
JOURNAL OF BIOLOGICAL CHEMISTRY

31263

Role of Hsp90 in ERAD-mediated Dislocation
cells (Fig. 3A). GA-induced toxin resistance could not, therefore, be attributed to the inactivation of GRP94. NECA-treated
cells were resistant to ricin, another AB toxin that uses the
ERAD system for A chain dislocation to the cytosol (Fig. 3B).
This observation was consistent with published results (32) and
demonstrated that NECA was functional at the concentration
used in our CT assay. Additional control experiments demonstrated that GA did not block the cytopathic activity of a CTA1
construct that was expressed directly in the cytosol of cells
transfected with a CTA1-encoding plasmid (27) (supplemental Fig. S1). The inhibitory effect of GA thus appeared to
involve an event upstream of toxin-target interactions. Furthermore, GA did not inhibit the forskolin-induced elevation of
intracellular cAMP: cells treated with GA and forskolin produced 100 ⫾ 2% of the cAMP levels recorded for cells treated
with forskolin alone (n ⫽ 3). Forskolin activates adenylate
cyclase without the input of Gs␣, so this observation demonstrated that GA did not directly inhibit the production of cAMP
by adenylate cyclase.
GA also inhibited CT activity in the ileal loop model of intoxication (Fig. 3C). Surgically sealed sections of intestine were
injected with 2 g/ml of CT in the absence or presence of GA.
Seven hours later, the CT-injected loop displayed the distended
morphology indicative of water accumulation resulting from
productive intoxication. In contrast, loops that were injected
with both CT and 15 M GA exhibited substantially attenuated
fluid accumulation and intestinal distension. GA derivatives
have been evaluated as anti-cancer agents in clinical trials (33,
34). The protective effect of GA in a physiological model of
TABLE 1
CTA1 exhibits a high affinity interaction with Hsp90 and a lower
affinity interaction with GRP94
On rates (ka), off rates (kd), and equilibrium dissociation constants (KD) between
CTA1 and either Hsp90 or GRP94 were calculated from the data presented in Fig. 2.
CTA1 binding partner
Hsp90
GRP94

ka

kd

KD

1/Ms

1/s

nM

9,929
1,537

7.8 ⫻ 10⫺5
4.5 ⫻ 10⫺4

7
292

intoxication suggests that it could also be used as a therapeutic
to prevent or possibly treat cholera.
Toxin resistance can result from an inhibition of toxin dislocation from the ER to the cytosol (9, 11, 13, 24). To determine if
GA blocked toxin export to the cytosol, we used an established
dislocation assay (24, 35) to monitor the appearance of CTA1 in
the cytosol of intoxicated HeLa cells (Fig. 4). Like CHO cells,
GA-treated HeLa cells were protected from CT as assessed by
cAMP production (data not shown). After a 30 min exposure to
CT at 4 °C, HeLa cells were chased for 2 h at 37 °C in the absence
of additional toxin. Separate organelle and cytosol fractions
were then collected from digitonin-permeabilized cells. Control experiments demonstrated the fidelity of our fractionation
protocol: Western blot analysis detected the majority of Hsp90
in the supernatant (i.e. cytosolic) fraction, while PDI, a soluble
ER protein, was found exclusively in the pellet fraction, which
contained the intact ER and other membranes (Fig. 4A). After
background subtraction, semi-quantitative analysis of the PDI
Western blot detected a negligible amount of PDI (0.5%) in the
supernatant fraction (n ⫽ 3). Additional Western blot analysis
with non-reducing SDS-PAGE was performed in order to track
the intracellular localization of CTA1 (Fig. 4B). The 21 kDa
CTA1 subunit is initially synthesized as part of a larger, 26 kDa
CTA precursor (1, 2). Proteolytic nicking of CTA generates a
disulfide-linked CTA1/CTA2 heterodimer, which is reductively cleaved in the ER; only the reduced CTA1 subunit enters
the cytosol. Consistent with these observations, we detected
both disulfide-linked CTA1/CTA2 and reduced CTA1 in the
organelle fractions but only detected reduced CTA1 in the
cytosol fractions. In comparison to the untreated control cells,
the distribution of cytosolic CTA1 was unaffected by NECA
treatment. However, GA-treated cells contained less cytosolic
CTA1 than either untreated or NECA-treated cells. It thus
appeared that Hsp90 function was required for efficient passage
of CTA1 into the cytosol.
To strengthen our Western blot analysis with an alternative
and quantitative detection method, we employed the technique
of SPR. HeLa cells exposed to CT at 4 °C were again fraction-

FIGURE 3. GA but not NECA inhibits CT intoxication. A, CHO cells were incubated with varying concentrations of CT in the absence of additional treatment,
in the presence of 0.1 M GA, or in the presence of 0.1 M NECA. After 2 h of continual toxin exposure, toxicity was assessed from the elevated levels of
intracellular cAMP. The means ⫾ S.E. of at least four independent experiments with triplicate samples are shown. B, CHO cells were incubated for 4 h with
varying concentrations of ricin in the absence or presence of 0.1 M NECA. Toxicity was then determined from the incorporation of [35S]methionine into newly
synthesized proteins. The averages ⫾ ranges of two independent experiments with triplicate samples are shown. C, surgically sealed sections of rat intestine
were injected with 2 g/ml of CT in the absence or presence of 15 M GA. Two other loops were injected with only 15 M GA or with PBS. Morphological
examination (inset) and the calculation of fluid accumulation were performed 7 h post-injection. Results presented in the graph represent the averages ⫾ S.D.
of data obtained from 4 rats.
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FIGURE 4. GA but not NECA inhibits CTA1 dislocation to the cytosol. HeLa cells were pulse-labeled at 4 °C for 30 min with 1 g/ml of CT. The cells were then
chased for 2 h at 37 °C in toxin-free medium containing no additions, 0.1 M GA, 0.1 M NECA, or 5 g/ml of BfA. Permeabilization of the plasma membrane with
digitonin was used to partition cell extracts into separate organelle (pellet; P) and cytosolic (supernatant; S) fractions. A, both fractions from untreated cells were
probed by Western blot to establish the distributions of cytosolic marker Hsp90 and ER marker PDI. B, both fractions from untreated (no treatment) or
drug-treated cells were probed for the presence of CTA1 by Western blot analysis of non-reducing SDS-PAGE gels. The upper band represents the disulfidelinked CTA1/CTA2 heterodimer; the middle band results from nonspecific cross-reactivity; and the lower band represents reduced CTA1. C, an SPR sensor slide
coated with an anti-CTA antibody was used to detect the cytosolic pool of CTA1 from untreated or drug-treated cells. D, media samples taken from cells at the
end of the chase were perfused over an SPR sensor slide coated with an anti-CTA antibody. For both C and D, CTA standards were perfused over the sensor slide
as positive controls. The cytosolic fraction and medium from unintoxicated cells were also perfused over the sensor slides as negative controls for panels C and
D, respectively. At the end of each experiment, bound sample was stripped from the sensor slide. One of four representative experiments is shown for each SPR
experiment.

ated into membrane and cytosolic components after a 2 h chase
at 37 °C. In this experiment, the cytosolic fractions were perfused over a SPR sensor slide that had been coated with an
anti-CTA antibody (Fig. 4C). A negligible background signal
was obtained from unintoxicated cells, whereas control cells
intoxicated in the absence of drug treatment produced a signal
that was comparable to the response obtained from the 0.1-ng
CTA standard (n ⫽ 4). The low level of cytosolic CTA1 in control cells was consistent with the known inefficiency of CT trafficking from the cell surface to the ER dislocation site (4, 7, 36).
NECA-treated cells produced an SPR signal similar to the
response obtained from the untreated control cells. In contrast,
GA-treated cells produced an SPR signal that was substantially
less than the response obtained from the untreated control
cells. Exposure of untreated or GA-treated cells to proteasome
inhibitors did not alter these results, which indicated the data
were not affected by potential toxin degradation in the cytosol
(supplemental Fig. S2). The detection of a minor pool of cytosolic CTA1 in GA-treated cells by SPR but not by Western blot
reflects the greater level of sensitivity provided by SPR-based
assays. CTA1 was not detected in the cytosol of cells treated
BfA, a drug that prevents CT transport from the cell surface to
the ER dislocation site (4, 7, 37).
Protein concentration is directly proportional to the SPRderived association rate constant (ka) (38), so we calculated the
levels of cytosolic CTA1 from a plot of the ka values for the CTA
standards. With this method, we estimated that 2.4-fold less
CTA1 was in the cytosol of GA-treated cells than in the cytosol
of untreated or NECA-treated cells (supplemental Table S1). A
substantial inhibition of intoxication resulting from reduced,
but not absent, levels of cytosolic CTA1 has previously been
reported (13, 14, 24). The degree of intoxication appears to be
influenced by numerous factors, including (i) the extent of
CTA1 dislocation to the cytosol; (ii) the rate of CTA1 degradation in the cytosol; (iii) CTA1 activity against Gs␣; and (iv) the
OCTOBER 8, 2010 • VOLUME 285 • NUMBER 41

de-activation of ADP-ribosylated Gs␣ by proteolysis or by the
action of ADP-ribosyl(arginine)protein hydrolase (9, 13, 14, 19,
24, 39 – 41). The balance between these factors usually favors
CTA1 activity against Gs␣ and, thus, productive intoxication.
However, as shown here and in previous work, this balance can
be shifted to protect cells from intoxication without completely
eliminating the cytosolic pool of CTA1.
To ensure that GA did not inhibit the intracellular trafficking
of CT, we screened media samples from toxin-treated cells for
the presence of free CTA1. The CT holotoxin travels by vesicle
carriers from the cell surface to the ER (3). Reduction and chaperone-assisted dissociation of CTA1 from the rest of the toxin
then allows the free A1 subunit to move from the ER to the
cytosol. In addition, a fraction of dissociated CTA1 enters the
secretory pathway and is released into the extracellular medium
(24, 36). Consistent with these observations, our SPR assay
detected the secretion of CTA1 from intoxicated HeLa cells
(Fig. 4D). Nearly equivalent amounts of CTA1 were secreted
into the medium of untreated cells and GA-treated cells. No
signal was obtained from the medium of BfA-treated cells, thus
demonstrating that toxin trafficking to the ER was a prerequisite for CTA1 secretion into the medium. The aforementioned
results were obtained with a SPR sensor slide that had been
coated with an anti-CTA antibody. When the media samples
were perfused over an SPR sensor slide that had been coated
with an antibody against the cell-binding CTB subunit, no positive signals were obtained (data not shown). Thus, the secreted
toxin was free CTA1 and not the CT holotoxin. Because
untreated and GA-treated cells released equivalent amounts of
free CTA1, GA did not appear to block holotoxin trafficking to
the ER, CTA1 dissociation from the rest of the toxin in the ER,
or the secretion of free CTA1.
To further demonstrate that GA inhibited the CTA1 dislocation event rather than an upstream CT trafficking step, we
combined our dislocation assay with a plasmid-based system to
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 5. GA inhibits dislocation of an ER-localized CTA1 construct. CHO
cells were transfected with a plasmid encoding a CTA1 subunit appended
with an ER-targeting signal sequence. Permeabilization of the plasma membrane with digitonin was used to partition cell extracts into separate
organelle (pellet; P) and cytosolic (supernatant; S) fractions. A, both fractions
from transfected cells were probed by Western blot to establish the distributions of Hsp90 and PDI. B, distribution of CTA1 immunoprecipitated from
transfected cells after a 1 h radiolabeling was visualized and quantified by
SDS-PAGE with PhosphorImager analysis. Experiments were performed with
untreated control cells, cells exposed to 0.1 M NECA, or cells exposed to 0.1
M GA. The upper band in the gel represents the population of CTA1 with an
intact, uncleaved signal sequence. The means ⫾ S.E. of three independent
experiments are presented in the graph.

express CTA1 directly in the ER of transfected CHO cells (12,
27). With this system, CTA1 is co-translationally inserted into
the ER and then dislocated back to the cytosol. Similar strategies have been used by other labs to monitor toxin dislocation
(10, 35, 42– 45). Control experiments again demonstrated the
fidelity of our fractionation protocol in CHO cells: Western blot
analysis detected Hsp90 mainly in the cytosolic fraction, while
PDI was only found in the organelle fraction (Fig. 5A). Consistent with the SPR-based dislocation assay which used exogenously applied toxin, the plasmid-based expression system
detected a 2.9-fold block of CTA1 dislocation in GA-treated
cells (Fig. 5B). No inhibitory effect on CTA1 dislocation was
observed for NECA-treated cells, thus demonstrating that the
GA-induced block of CTA1 dislocation did not result from an
effect on GRP94 (Fig. 5B).
To confirm the specific role of Hsp90 in CTA1 dislocation,
we used RNAi to deplete the cellular pool of Hsp90 (Fig. 6).
Western blot analysis confirmed the near-complete elimination of Hsp90 protein after transfection with the RNAi construct targeting Hsp90 but not after transfection with the control RNAi construct (Fig. 6A). Cells with reduced levels of
Hsp90 were highly resistant to CT intoxication (Fig. 6B) and did
not effectively deliver CTA1 to the cytosol as assessed by our
SPR-based dislocation assay (Fig. 6C). The nearly identical results obtained by drug treatment and RNAi indicated that our
data were not influenced by off-target effects from a single
experimental technique.
A complete inhibition of CT intoxication was recorded for
the RNAi experiment but not for the GA experiment, which
suggested that RNAi was more effective at abrogating Hsp90
function than drug treatment. Consistent with this interpretation, we found a greater reduction of cytosolic CTA1 in the
RNAi experiment (3.2-fold) than in the GA experiment (2.4fold) (supplemental Table S1). The residual pool of CTA1 that
appeared in the cytosol of cells lacking Hsp90 was not sufficient
to produce a cAMP response, possibly because of compensating cellular processes to prevent or reverse CT activity against
Gs␣ (14, 39 – 41). The complete inhibition of CT-induced

FIGURE 6. Hsp90 depletion prevents CT intoxication and CTA1 dislocation. HeLa cells were mock transfected, transfected with control siRNA, or transfected
with Hsp90 siRNA. A, cell extracts were probed by Western blot analysis with an anti-Hsp90 antibody or an anti-actin antibody. After standardization to the
actin-loading control, transfection with the Hsp90 siRNA was estimated to reduce Hsp90 protein levels to 10 ⫾ 6% (n ⫽ 3) of control levels from the mocktransfected cells. B, transfected cells were exposed to varying concentrations of CT for 2 h before intracellular cAMP levels were determined. The means ⫾ S.E.
of four independent experiments with triplicate samples are shown. C, SPR sensor slide coated with an anti-CTA antibody was used to detect the cytosolic pool
of CTA1 from transfected cells. CTA standards were perfused over the sensor slide as positive controls, while a cytosolic fraction generated from unintoxicated
cells was used as a negative control. One of three representative experiments is shown.
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cAMP production upon RNAi knockdown of Hsp90 was
remarkable, and it highlighted the importance of Hsp90 for the
CT intoxication process.
Recently, Hsp90 was shown to be involved with the renaturation of an unfolded protein that had passed from the cell surface to the ER and from the ER to the cytosol (46). The Hsp90assisted refolding of denatured proteins may be linked to its
dislocation activity: by coupling dislocation with refolding,
Hsp90 would prevent the (re)folded CTA1 protein from sliding
back into the dislocation pore. This ratchet mechanism would
thus provide the driving force for CTA1 dislocation. Although a
previous report suggested the ATP-dependent dislocation of
CTA1 does not require cytosolic factors (10), we and others (35,
47) have detected a membrane-associated pool of Hsp90 which
may have been purified with the microsomal preparation used
in that study. Our work clearly shows that Hsp90 exhibits a high
affinity interaction with CTA1, and that the disruption of this
interaction inhibits both CTA1 dislocation and CT intoxication
in vivo.
Hsp90 is also involved with ricin intoxication, although in
this case Hsp90 apparently prepares the catalytic A chain of
ricin for proteasomal degradation (32). The GA-induced inactivation of Hsp90 thus allows ricin A chain to accumulate in the
cytosol and thereby generates cellular sensitization to this ABtype plant toxin. In contrast, we have shown that GA-treated
cells are resistant to CT. The dislocation of ricin A chain also
involves GRP94 and p97 (32, 48), whereas these proteins do not
appear to be active in CTA1 dislocation (20, 21). Thus, while
both CTA1 and ricin A chain exploit ERAD for passage into the
cytosol, distinct molecular events are involved with the dislocation of the two toxins.
ERAD substrates, including ricin A chain, are usually exported
to the cytosol through the action of p97 (16, 48). However, there is
also a p97-independent dislocation route for some ERAD substrates such as CTA1 (20, 21, 49, 50). This report demonstrates
that the p97-independent dislocation of CTA1 requires Hsp90
function. We have thus established a new role for Hsp90 in the
extraction of a soluble ERAD substrate from the ER.
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